Due to some reasons, including lesser effectiveness of calcitonin than BPs, increased risk of cancer by its long-term usage, and less availability compared to BPs, calcitonin is typically not used for treating osteoporosis unless to relief acute pain (onset <10 days) secondary to osteoporotic fracture. Here, CALCA is linked to cancer.